Abstract is: The genus Marburgvirus is the taxonomic home of Marburg marburgvirus, whose members are the two known marburgviruses, Marburg virus (MARV) and Ravn virus (RAVV). Both viruses cause Marburg virus disease in humans and nonhuman primates, a form of viral hemorrhagic fever. Both are Select agents, World Health Organization Risk Group 4 Pathogens (requiring Biosafety Level 4-equivalent containment), National Institutes of Health/National Institute of Allergy and Infectious Diseases Category A Priority Pathogens, Centers for Disease Control and Prevention Category A Bioterrorism Agents, and are listed as Biological Agents for Export Control by the Australia Group.
| taxon | Q16521 |
| P10585 | Catalogue of Life ID | 5L6M |
| P9272 | DeCS ID | 8550 |
| P830 | Encyclopedia of Life ID | 80654 |
| P646 | Freebase ID | /m/0dlhjjb |
| P846 | GBIF taxon ID | 10476779 |
| P5055 | IRMNG ID | 1015798 |
| P3827 | JSTOR topic ID (archived) | marburgvirus |
| P486 | MeSH descriptor ID | D029024 |
| P672 | MeSH tree code | B04.820.480.937.300.650 |
| P6366 | Microsoft Academic ID | 2779428490 |
| P685 | NCBI taxonomy ID | 186537 |
| P10376 | ScienceDirect topic ID | neuroscience/marburgvirus |
| medicine-and-dentistry/marburgvirus | ||
| immunology-and-microbiology/marburgvirus | ||
| biochemistry-genetics-and-molecular-biology/marburgvirus | ||
| P11143 | WikiProjectMed ID | Marburgvirus |
| P850 | WoRMS-ID for taxa | 600282 |
| P138 | named after | Marburg | Q3869 |
| P171 | parent taxon | Filoviridae | Q46305 |
| P225 | taxon name | Marburgvirus | |
| P105 | taxon rank | genus | Q34740 |
| P427 | taxonomic type | Marburg marburgvirus | Q6755280 |
| P1424 | topic's main template | Template:Taxonomy/Marburgvirus | Q113517788 |
| Q34225775 | "Marburg virus" (Vervet monkey disease agent) in tissue cultures |
| Q46811138 | "Marburg virus" antigen demonstration by immunofluorescence in the organs of infected guinea pigs |
| Q35798489 | A Comparison of the Pathogenesis of Marburg Virus Disease in Humans and Nonhuman Primates and Evaluation of the Suitability of These Animal Models for Predicting Clinical Efficacy under the 'Animal Rule'. |
| Q47159182 | A Single Amino Acid Change in the Marburg Virus Glycoprotein Arises during Serial Cell Culture Passages and Attenuates the Virus in a Macaque Model of Disease |
| Q38818595 | A Single Amino Acid Change in the Marburg Virus Matrix Protein VP40 Provides a Replicative Advantage in a Species-Specific Manner |
| Q40058018 | A bioluminescent imaging mouse model for Marburg virus based on a pseudovirus system |
| Q40725129 | A comparative evaluation of an immunoenzyme analytical method using a fluorogenic or chromogenic substrate in determining the Marburg virus antigen |
| Q53856813 | A comparative study of the immunological indices in guinea pigs administered an inactivated Marburg virus |
| Q46864277 | A comparative study of the in-vitro interaction of the Marburg virus with macrophages from different animal species |
| Q53858677 | A comparison of the methods of fluorescent antibodies and solid-phase immunoenzyme analysis in the detection of Marburg virus antibodies |
| Q45813485 | A critical study of monkey sera for the presence of antibody against the Marburg virus |
| Q37504760 | A hamster model for Marburg virus infection accurately recapitulates Marburg hemorrhagic fever |
| Q43211412 | A hitherto unknown infectious disease contracted from monkeys. "Marburg-virus" disease |
| Q34033322 | A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge |
| Q36310941 | A parallel genome-wide RNAi screening strategy to identify host proteins important for entry of Marburg virus and H5N1 influenza virus |
| Q46527850 | A promising method for preparative production and purification of the Marburg virus |
| Q51785212 | A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates. |
| Q44090927 | A single shot against Ebola and Marburg virus |
| Q46893658 | A strain of "Marburg virus" (Rhabdovirus simiae) pathogenic to mice |
| Q40708374 | AVI-7288 for Marburg Virus in Nonhuman Primates and Humans |
| Q34717923 | Activation of triggering receptor expressed on myeloid cells-1 on human neutrophils by marburg and ebola viruses |
| Q33461401 | Acute fever caused by Marburg virus |
| Q44239313 | Acylation of the Marburg virus glycoprotein |
| Q45738876 | Adverse effects of MVA-T7 on the transport of Marburg virus glycoprotein |
| Q40349753 | Aerosol exposure to the angola strain of marburg virus causes lethal viral hemorrhagic Fever in cynomolgus macaques. |
| Q64361360 | After Marburg, Ebola |
| Q36043164 | Amino Acid Residue at Position 79 of Marburg Virus VP40 Confers Interferon Antagonism in Mouse Cells |
| Q40602517 | An active site mutation increases the polymerase activity of the guinea pig-lethal Marburg virus |
| Q45154550 | An experimental study of the contact transmission of the Marburg virus |
| Q21131118 | Animal models for Ebola and Marburg virus infections |
| Q43211410 | Antibodies in Primates to the Marburg Virus |
| Q50034302 | Antibody Responses to Marburg Virus in Egyptian Rousette Bats and Their Role in Protection against Infection |
| Q35299989 | Antibody-dependent enhancement of Marburg virus infection |
| Q45758605 | Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants |
| Q40625399 | Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses |
| Q46782312 | Assay for level of Marburg virus in blood and isolates from experimentally infected animals |
| Q38062931 | Assembly of the Marburg virus envelope |
| Q40042145 | Basolateral budding of Marburg virus: VP40 retargets viral glycoprotein GP to the basolateral surface |
| Q37421851 | Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene |
| Q39486455 | Biophysical characterization and conformational stability of Ebola and Marburg virus-like particles |
| Q44121333 | Breakdown of paraendothelial barrier function during Marburg virus infection is associated with early tyrosine phosphorylation of platelet endothelial cell adhesion molecule-1. |
| Q40202125 | Budding of Marburgvirus is associated with filopodia |
| Q34995659 | Calculation of incubation period and serial interval from multiple outbreaks of Marburg virus disease |
| Q41610714 | Carbohydrate structure of Marburg virus glycoprotein |
| Q39417023 | Cathepsins B and L activate Ebola but not Marburg virus glycoproteins for efficient entry into cell lines and macrophages independent of TMPRSS2 expression. |
| Q45391085 | Cellular immune response to Marburg virus infection in cynomolgus macaques |
| Q40683464 | Certain pathogenetic characteristics of a disease in monkeys in infected with the Marburg virus by an airborne route |
| Q40734534 | Changes in the blood serum aminotransferase activity in the experimental infection of Cercopithecus aethiops monkeys with the Marburg virus |
| Q54172076 | Changes of female genitalia during Marburg virus disease |
| Q54128407 | Characteristics of Filoviridae: Marburg and Ebola viruses. |
| Q40228983 | Characterization of Marburg virus glycoprotein in viral entry. |
| Q35223870 | Characterization of Marburg virus morphology |
| Q34063229 | Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya |
| Q44737820 | Characterization of monoclonal antibodies to Marburg virus (strain Musoke) glycoprotein and identification of two protective epitopes |
| Q34404757 | Characterization of monoclonal antibodies to Marburg virus nucleoprotein (NP) that can be used for NP-capture enzyme-linked immunosorbent assay |
| Q45502568 | Chlorella virus Marburg topoisomerase II: high DNA cleavage activity as a characteristic of Chlorella virus type II enzymes |
| Q39635739 | Clinical aspects of Marburg virus infection |
| Q30761472 | Clinical documentation and data transfer from Ebola and Marburg virus disease wards in outbreak settings: health care workers' experiences and preferences |
| Q40685398 | Clinical-virusological characteristics of disease in guinea pigs, infected by the Marburg virus aerogenically |
| Q45751708 | Co- and posttranslational modifications and functions of Marburg virus proteins. |
| Q36255716 | Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges |
| Q44090018 | Comments on the article "Marburg and Ebola virus infections in laboratory non-human primates: a literature review". Soren Schou and Axel Kornerup Hansen. Comparative Medicine, 2000. 50:108-123. |
| Q40402342 | Communicable diseases. 6. Marburg virus disease |
| Q34223117 | Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. |
| Q36043232 | Comparison of the Pathogenesis of the Angola and Ravn Strains of Marburg Virus in the Outbred Guinea Pig Model |
| Q33653597 | Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems |
| Q40688015 | Complete nucleotide sequences of Marburg virus genes 5 and 6 encoding VP30 and VP24 proteins. |
| Q34544615 | Complex adenovirus-vectored vaccine protects guinea pigs from three strains of Marburg virus challenges |
| Q40809864 | Conservation of the 3' terminal nucleotide sequences of Ebola and Marburg virus |
| Q39759620 | Conserved motifs within Ebola and Marburg virus VP40 proteins are important for stability, localization, and subsequent budding of virus-like particles |
| Q40295821 | Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor |
| Q36043284 | Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection |
| Q55128618 | Correction: A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates. |
| Q42591160 | Correction: Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs. |
| Q40073532 | Corrigendum: Differential transcriptional responses to Ebola and Marburg virus infection in bat and human cells |
| Q34566171 | Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine |
| Q21090169 | Cryo-electron tomography of Marburg virus particles and their morphogenesis within infected cells |
| Q27681924 | Crystal Structure of Marburg Virus VP24 |
| Q36523972 | Crystal Structure of Marburg Virus VP40 Reveals a Broad, Basic Patch for Matrix Assembly and a Requirement of the N-Terminal Domain for Immunosuppression |
| Q27671801 | Crystal Structure of the Marburg Virus GP2 Core Domain in Its Postfusion Conformation |
| Q40050678 | Crystal Structure of the Marburg Virus Nucleoprotein Core Domain Chaperoned by a VP35 Peptide Reveals a Conserved Drug Target for Filovirus |
| Q37560760 | Crystal Structure of the Marburg Virus VP35 Oligomerization Domain |
| Q40213399 | DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus |
| Q40484185 | De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses |
| Q34461912 | Deep sequencing identifies noncanonical editing of Ebola and Marburg virus RNAs in infected cells |
| Q33794406 | Deep-sequencing of Marburg virus genome during sequential mouse passaging and cell-culture adaptation reveals extensive changes over time |
| Q27303778 | Delayed Time-to-Treatment of an Antisense Morpholino Oligomer Is Effective against Lethal Marburg Virus Infection in Cynomolgus Macaques |
| Q33878907 | Democratic Republic of the Congo: between civil war and the Marburg virus. International Committee of Technical and Scientific Coordination of the Durba Epidemic |
| Q46478058 | Demonstration of complement fixing antibodies against Marburg virus in 22 patients using a cell culture antigen |
| Q34225071 | Demonstration of the "Marburg virus" in the patient |
| Q40425536 | Design of equine serum-based Marburg virus immunoglobulin |
| Q40273257 | Detection and antigenic characteristics of the recombinant nucleocapsid proteins of Lassa and Marburg viruses |
| Q33564915 | Detection of lipid-induced structural changes of the Marburg virus matrix protein VP40 using hydrogen/deuterium exchange-mass spectrometry |
| Q44887175 | Detection of the "Marburg Virus" in patients |
| Q45813845 | Detection of the antigen of the "Marburg Virus" in the organs of infected guinea-pigs by immunofluorescence |
| Q34593045 | Determination of specific antibody responses to the six species of ebola and Marburg viruses by multiplexed protein microarrays |
| Q54261116 | Development and characterization of a guinea pig model for Marburg virus. |
| Q34104279 | Development and evaluation of a fluorogenic 5'-nuclease assay to identify Marburg virus |
| Q33963454 | Development and evaluation of a simple assay for Marburg virus detection using a reverse transcription-loop-mediated isothermal amplification method |
| Q36310674 | Development of a model for marburgvirus based on severe-combined immunodeficiency mice |
| Q42266175 | Development of a reverse genetics system to generate recombinant Marburg virus derived from a bat isolate |
| Q36379341 | Development of treatment strategies to combat Ebola and Marburg viruses |
| Q64246691 | Diagnostics for filovirus detection: impact of recent outbreaks on the diagnostic landscape |
| Q33826885 | Different potential of C-type lectin-mediated entry between Marburg virus strains |
| Q36619514 | Differential Regulation of Interferon Responses by Ebola and Marburg Virus VP35 Proteins |
| Q40616449 | Differential induction of cellular detachment by envelope glycoproteins of Marburg and Ebola (Zaire) viruses |
| Q36155931 | Differential transcriptional responses to Ebola and Marburg virus infection in bat and human cells |
| Q35738767 | Digital sensing and sizing of vesicular stomatitis virus pseudotypes in complex media: a model for Ebola and Marburg detection |
| Q28388484 | Dimerization Controls Marburg Virus VP24-dependent Modulation of Host Antioxidative Stress Responses |
| Q33501744 | Dimerization of tetherin is not essential for its antiviral activity against Lassa and Marburg viruses |
| Q36432717 | Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections |
| Q37351948 | Discovery of common marburgvirus protective epitopes in a BALB/c mouse model |
| Q37040575 | Disease modeling for Ebola and Marburg viruses |
| Q39591297 | Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses |
| Q34530281 | Distribution of Marburg virus in Africa: An evolutionary approach |
| Q37411610 | Drug targets in infections with Ebola and Marburg viruses |
| Q21559476 | Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates |
| Q40590543 | Dynamics of expression of Marburg and Ebola virus antigens in infected Vero cells |
| Q36674519 | Early detection of antigen and estimation of virus yield in specimens from patients with Marburg virus disease |
| Q40071302 | Ebola Virus and Marburg Virus in Human Milk Are Inactivated by Holder Pasteurization |
| Q37896703 | Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. |
| Q38463251 | Ebola and Marburg hemorrhagic fever viruses: update on filoviruses |
| Q40624897 | Ebola and Marburg virus antibody prevalence in selected populations of the Central African Republic |
| Q38231522 | Ebola and Marburg virus diseases in Africa: increased risk of outbreaks in previously unaffected areas? |
| Q30234637 | Ebola and Marburg virus vaccines |
| Q40528278 | Ebola and Marburg virus-like particles activate human myeloid dendritic cells |
| Q43675288 | Ebola and Marburg virus: entomologic hypothesis to confirm |
| Q40545283 | Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation |
| Q36352316 | Ebola and Marburg viruses: pathogenesis and development of countermeasures |
| Q34511002 | Ebola and Marburg viruses: the humans strike back |
| Q39588172 | Ebola and marburg viruses: I. Some ultrastructural differences between strains when grown in vero cells |
| Q39712294 | Ebola and marburg viruses: II. Their development within vero cells and the extra-cellular formation of branched and torus forms |
| Q40560377 | Ebola virus and Marburg virus |
| Q27008824 | Ebola virus disease and Marburg disease in pregnancy: a review and management considerations for filovirus infection |
| Q34722409 | Ebolavirus and Marburgvirus: insight the Filoviridae family |
| Q35193047 | Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry |
| Q42364377 | Ecological Niche Modeling for Filoviruses: A Risk Map for Ebola and Marburg Virus Disease Outbreaks in Uganda. |
| Q45286681 | Ecology of "marburgvirus" (Rhabdovirus simiae) |
| Q40824508 | Ecology of Marburg and Ebola viruses: speculations and directions for future research |
| Q40664032 | Effectiveness of virus-specific proteins in immunogenesis during experimental Marburg fever |
| Q47216285 | Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus. |
| Q40077926 | Egyptian rousette bats maintain long-term protective immunity against Marburg virus infection despite diminished antibody levels |
| Q44090058 | Emerging diseases. On the trail of Ebola and Marburg viruses |
| Q33970750 | Enzyme-linked immunosorbent assays for detection of antibodies to Ebola and Marburg viruses using recombinant nucleoproteins |
| Q34054088 | Epidemiologic Investigation of Marburg Virus Disease, Southern Africa, 1975 * |
| Q43827238 | Establishment and application of an infectious virus-like particle system for Marburg virus |
| Q33417197 | Establishment and characterization of a lethal mouse model for the Angola strain of Marburg virus |
| Q45893786 | Etymologia: Marburg Virus |
| Q37582945 | Evasion of interferon responses by Ebola and Marburg viruses |
| Q35895285 | Experimental Inoculation of Egyptian Rousette Bats (Rousettus aegyptiacus) with Viruses of the Ebolavirus and Marburgvirus Genera |
| Q40256210 | Experimental respiratory Marburg virus haemorrhagic fever infection in the common marmoset (Callithrix jacchus). |
| Q42231570 | Exploring the mechanism how Marburg virus VP35 recognizes and binds dsRNA by molecular dynamics simulations and free energy calculations |
| Q22305519 | Filoviral immune evasion mechanisms |
| Q34056967 | Filoviridae: a taxonomic home for Marburg and Ebola viruses? |
| Q38599899 | Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus |
| Q30995893 | Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses |
| Q30377150 | Fold prediction of VP24 protein of Ebola and Marburg viruses using de novo fragment assembly. |
| Q34583823 | Forty years of marburg virus |
| Q36395831 | Forty-five years of Marburg virus research |
| Q38696255 | From hybridomas to a robust microalgal-based production platform: molecular design of a diatom secreting monoclonal antibodies directed against the Marburg virus nucleoprotein |
| Q36305916 | Generation and characterization of protective antibodies to Marburg virus. |
| Q40541847 | Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein |
| Q35755118 | Genomic analysis of codon usage shows influence of mutation pressure, natural selection, and host features on Marburg virus evolution |
| Q45399666 | Genomic differences between guinea pig lethal and nonlethal Marburg virus variants |
| Q36054652 | Geographic potential of disease caused by Ebola and Marburg viruses in Africa. |
| Q38335344 | Glycosylation and oligomerization of the spike protein of Marburg virus |
| Q40480023 | Good news for Marburg virus workers. |
| Q43211422 | Green Monkey Disease ("Marburg Virus" Disease): A New Zoonosis |
| Q38977827 | Haemorrhagic Fever in Africa due to marburg-ebola viruses |
| Q40847249 | Haemorrhagic fever in Gabon. I. Incidence of Lassa, Ebola and Marburg viruses in Haut-Ogooué. |
| Q34661133 | High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses |
| Q39796970 | Homo-oligomerization of Marburgvirus VP35 is essential for its function in replication and transcription |
| Q36858879 | How Ebola and Marburg viruses battle the immune system |
| Q30151580 | How severe and prevalent are Ebola and Marburg viruses? A systematic review and meta-analysis of the case fatality rates and seroprevalence |
| Q37163676 | Human Survivors of Disease Outbreaks Caused by Ebola or Marburg Virus Exhibit Cross-Reactive and Long-Lived Antibody Responses |
| Q43210762 | Human disease from monkeys (Marburg virus). |
| Q35299826 | Identification of amino acids in Marburg virus VP40 that are important for virus-like particle budding |
| Q40156803 | Immune Response to Marburg Virus Angola Infection in Nonhuman Primates |
| Q38616381 | Immunoglobulin M and G responses measured by immunofluorescence in patients with Lassa or Marburg virus infections |
| Q40468233 | Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses. |
| Q45769541 | Inactivated Marburg virus elicits a nonprotective immune response in Rhesus monkeys |
| Q44088999 | Inactivating Lassa and Marburg/Ebola viruses |
| Q34057056 | Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation |
| Q39605104 | Infection and activation of monocytes by Marburg and Ebola viruses |
| Q39859903 | Infections by Marburg and Ebola viruses: guide for their diagnosis, treatment and control |
| Q35706815 | Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists |
| Q24652263 | Inhibition of Lassa and Marburg virus production by tetherin |
| Q36414333 | Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein |
| Q40512402 | Inhibition of Marburg virus protein expression and viral release by RNA interference |
| Q35857432 | Interaction of Tsg101 with Marburg virus VP40 depends on the PPPY motif, but not the PT/SAP motif as in the case of Ebola virus, and Tsg101 plays a critical role in the budding of Marburg virus-like particles induced by VP40, NP, and GP. |
| Q27323035 | Interaction with Tsg101 is necessary for the efficient transport and release of nucleocapsids in marburg virus-infected cells |
| Q45753146 | Interactions of Marburg virus nucleocapsid proteins |
| Q41154586 | Intracellular transport and processing of the Marburg virus surface protein in vertebrate and insect cells |
| Q39603524 | Investigation of the Lipid Binding Properties of the Marburg Virus Matrix Protein VP40. |
| Q43525304 | Is Marburg virus enzootic in Gabon? |
| Q33724625 | Isolated Case of Marburg Virus Disease, Kampala, Uganda, 2014. |
| Q54083606 | Isolation and identification of the "Marburg virus" |
| Q34055935 | Isolation of Marburg-like virus from a case of haemorrhagic fever in Zaire |
| Q21090516 | Isolation of genetically diverse Marburg viruses from Egyptian fruit bats |
| Q35076563 | Key genomic changes necessary for an in vivo lethal mouse marburgvirus variant selection process |
| Q40039621 | Knowledge and attitude towards Ebola and Marburg virus diseases in Uganda using quantitative and participatory epidemiology techniques |
| Q41358863 | Lack of Marburg Virus Transmission From Experimentally Infected to Susceptible In-Contact Egyptian Fruit Bats |
| Q21261526 | Large serological survey showing cocirculation of Ebola and Marburg viruses in Gabonese bat populations, and a high seroprevalence of both viruses in Rousettus aegyptiacus |
| Q36012840 | Large-Scale Screening and Identification of Novel Ebola Virus and Marburg Virus Entry Inhibitors |
| Q34515519 | Lassa and Marburg viruses elicit distinct host transcriptional responses early after infection |
| Q40904967 | Lassa fever and Marburg virus disease. |
| Q27478160 | Lassa fever, Marburg and Ebola virus diseases and other exotic diseases: is there a risk to Canada? |
| Q54227404 | Lectin Affinity Plasmapheresis for Middle East Respiratory Syndrome-Coronavirus and Marburg Virus Glycoprotein Elimination. |
| Q38498830 | Lessons from the Marburg virus epidemic in Durba, Democratic Republic of the Congo (1998-2000) |
| Q45423875 | Lessons from the outbreak of Marburg virus |
| Q36370336 | Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses |
| Q33987611 | Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses |
| Q30544040 | Live-cell imaging of Marburg virus-infected cells uncovers actin-dependent transport of nucleocapsids over long distances |
| Q36422879 | Local Mutational Pressures in Genomes of Zaire Ebolavirus and Marburg Virus |
| Q41714726 | Lyophilisation of influenza, rabies and Marburg lentiviral pseudotype viruses for the development and distribution of a neutralisation -assay-based diagnostic kit. |
| Q40385420 | Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization |
| Q45729865 | Mapping of two dominant sites of VP35 of Marburg virus. |
| Q30204337 | Mapping the zoonotic niche of Marburg virus disease in Africa |
| Q27487381 | Marburg Virus Disease |
| Q27490714 | Marburg Virus Evades Interferon Responses by a Mechanism Distinct from Ebola Virus |
| Q54206968 | Marburg Virus Infection in Egyptian Rousette Bats, South Africa, 2013-20141. |
| Q27015752 | Marburg Virus Reverse Genetics Systems |
| Q36043182 | Marburg Virus VP24 Protein Relieves Suppression of the NF-κB Pathway Through Interaction With Kelch-like ECH-Associated Protein 1. |
| Q27673907 | Marburg Virus VP35 Can Both Fully Coat the Backbone and Cap the Ends of dsRNA for Interferon Antagonism |
| Q46303675 | Marburg and Ebola Virus Infections: A Guide for their Diagnosis, Management, and Control |
| Q44088993 | Marburg and Ebola virus antibodies in Kenyan primates |
| Q33944983 | Marburg and Ebola virus infections in laboratory non-human primates: a literature review. |
| Q33983654 | Marburg and Ebola viruses as aerosol threats |
| Q40674438 | Marburg and Ebola viruses. |
| Q34561977 | Marburg hemorrhagic fever associated with multiple genetic lineages of virus |
| Q45813534 | Marburg virus |
| Q46728175 | Marburg virus |
| Q43207829 | Marburg virus |
| Q40433085 | Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. |
| Q35076858 | Marburg virus VP40 antagonizes interferon signaling in a species-specific manner. |
| Q45263062 | Marburg virus and the mountain of Elgon |
| Q34697130 | Marburg virus disease |
| Q44070831 | Marburg virus disease--an indicator case in South Africa |
| Q40319119 | Marburg virus disease. The diagnosis and management of suspected cases |
| Q43606305 | Marburg virus disease: epidemiology, symptomatology, management and prognosis |
| Q36642730 | Marburg virus gene 4 encodes the virion membrane protein, a type I transmembrane glycoprotein. |
| Q35857049 | Marburg virus glycoprotein GP2: pH-dependent stability of the ectodomain α-helical bundle |
| Q42407741 | Marburg virus in fruit bat, Kenya |
| Q38864560 | Marburg virus inclusions: A virus-induced microcompartment and interface to multivesicular bodies and the late endosomal compartment |
| Q21090111 | Marburg virus infection detected in a common African bat |
| Q45813487 | Marburg virus infection in monkeys. Ultrastructural studies |
| Q35852525 | Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA. |
| Q34081316 | Marburg virus structure revealed in detail |
| Q38848150 | Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses. |
| Q45352871 | Marburg virus uses a mask to evade immune detection. |
| Q34479873 | Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. |
| Q34098909 | Marburg virus vaccines: comparing classical and new approaches |
| Q42612213 | Marburg virus, a filovirus: méssenger RNAs, gene order, and regulatory elements of the replication cycle |
| Q42628113 | Marburg virus-like particles by co-expression of glycoprotein and matrix protein in insect cells induces immune responses in mice |
| Q38840884 | Marburg virus-like particles produced in insect cells induce neutralizing antibodies in rhesus macaques. |
| Q34340775 | Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection |
| Q53862580 | Marburg virus: the first determined nucleotide sequence of two genes |
| Q40848509 | Marburg, Ebola and Rift Valley Fever virus antibodies in East African primates |
| Q40870804 | Marburg, Ebole and Lassa virus infections |
| Q40874609 | Marburg, Lassa and Ebola virus as cause of hemorrhagic fever |
| Q34054741 | Marburg-virus disease in Kenya |
| Q24548936 | Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola |
| Q40214327 | Marburgvirus hijacks nrf2-dependent pathway by targeting nrf2-negative regulator keap1. |
| Q64359215 | Marburgvirus in Egyptian Fruit Bats, Zambia |
| Q34576189 | Marburgvirus nucleoprotein-capture enzyme-linked immunosorbent assay using monoclonal antibodies to recombinant nucleoprotein: detection of authentic Marburgvirus |
| Q42939796 | Marburgvirus resurgence in Kitaka Mine bat population after extermination attempts, Uganda |
| Q35132756 | Mechanism of human antibody-mediated neutralization of Marburg virus |
| Q38994258 | Membrane insertion of fusion peptides from Ebola and Marburg viruses studied by replica-exchange molecular dynamics simulations. |
| Q45407106 | Micro-scale signature of purifying selection in Marburg virus genomes |
| Q37651878 | Modelling filovirus maintenance in nature by experimental transmission of Marburg virus between Egyptian rousette bats |
| Q30277312 | Molecular architecture of the nucleoprotein C-terminal domain from the Ebola and Marburg viruses |
| Q40619621 | Monoclonal antibodies to Ebola virus: isolation, characteristics, and study of cross reactivity with Marburg virus |
| Q40632723 | Monoclonal antibodies to Marburg virus proteins and their immunochemical characteristics |
| Q34774783 | Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses |
| Q40724401 | Morphology of Marburg virus NP-RNA. |
| Q27011569 | Mouse models for filovirus infections |
| Q40474924 | Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice. |
| Q38858365 | Multidistrict Outbreak of Marburg Virus Disease-Uganda, 2012. |
| Q40266502 | Multiplex real-time PCR method for rapid detection of Marburg virus and Ebola virus |
| Q40277987 | Multivesicular bodies as a platform for formation of the Marburg virus envelope |
| Q36845986 | Natural History of Aerosol Exposure with Marburg Virus in Rhesus Macaques. |
| Q36654325 | No evidence for the involvement of the argasid tick Ornithodoros faini in the enzootic maintenance of marburgvirus within Egyptian rousette bats Rousettus aegyptiacus |
| Q28830618 | Novel Chemical Ligands to Ebola Virus and Marburg Virus Nucleoproteins Identified by Combining Affinity Mass Spectrometry and Metabolomics Approaches |
| Q38785678 | Novel activities by ebolavirus and marburgvirus interferon antagonists revealed using a standardized in vitro reporter system |
| Q37007013 | Novel mutations in Marburg virus glycoprotein associated with viral evasion from antibody mediated immune pressure |
| Q21245136 | Nucleocapsid formation and RNA synthesis of Marburg virus is dependent on two coiled coil motifs in the nucleoprotein |
| Q34053179 | On the hitherto unknown, in monkeys originating infectious disease: Marburg virus disease |
| Q37053561 | One-Step Reverse Transcription-Polymerase Chain Reaction for Ebola and Marburg Viruses |
| Q37255209 | Oral shedding of Marburg virus in experimentally infected Egyptian fruit bats (Rousettus aegyptiacus). |
| Q40511834 | Outbreak of Marburg virus hemorrhagic fever--Angola, October 1, 2004-March 29, 2005. |
| Q55065905 | Outbreake of Marburg virus disease in Johannesburg. |
| Q45283680 | Pathological anatomy of the "Marburg virus" disease (the so-called "Marburg monkey disease") |
| Q39445116 | Phosphorylation of Marburg virus NP region II modulates viral RNA synthesis |
| Q43706614 | Phosphorylation of Marburg virus VP30 at serines 40 and 42 is critical for its interaction with NP inclusions. |
| Q39461698 | Phosphorylation of Marburg virus matrix protein VP40 triggers assembly of nucleocapsids with the viral envelope at the plasma membrane |
| Q36209292 | Phylogenetic assessment of filoviruses: how many lineages of Marburg virus? |
| Q40784140 | Physicochemical Properties of Marburg Virus: Evidence for Three Distinct Virus Strains and Their Relationship to Ebola Virus |
| Q34055826 | Physicochemical inactivation of Lassa, Ebola, and Marburg viruses and effect on clinical laboratory analyses |
| Q40054096 | Plasma membrane association facilitates conformational changes in the Marburg virus protein VP40 dimer. |
| Q47548534 | Post-exposure treatments for Ebola and Marburg virus infections |
| Q34519791 | Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment |
| Q35877126 | Postexposure treatment of Marburg virus infection |
| Q26765404 | Presence and Persistence of Ebola or Marburg Virus in Patients and Survivors: A Rapid Systematic Review |
| Q45387733 | Production and characterization of monoclonal antibodies to nucleoprotein of Marburg virus |
| Q52485607 | Propagation of "Marburg virus" (Vervet monkey disease agent) in Aedes aegypti |
| Q36088118 | Prospects for immunisation against Marburg and Ebola viruses |
| Q37520171 | Protection against lethal Marburg virus infection mediated by lipid encapsulated small interfering RNA. |
| Q35675647 | Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs |
| Q45744301 | Proteolytic processing of Marburg virus glycoprotein |
| Q42601510 | Pygmy populations seronegative for Marburg virus |
| Q30472174 | Quantitative studies of heteropolymer-mediated binding of inactivated Marburg virus to the complement receptor on primate erythrocytes |
| Q40433153 | Rapid assembly of sensitive antigen-capture assays for Marburg virus, using in vitro selection of llama single-domain antibodies, at biosafety level 4. |
| Q27471311 | Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. |
| Q64051850 | Recent advances in marburgvirus research |
| Q35557172 | Recombinant Marburg virus expressing EGFP allows rapid screening of virus growth and real-time visualization of virus spread |
| Q38926381 | Recombinant Marburg viruses containing mutations in the IID region of VP35 prevent inhibition of Host immune responses |
| Q35557184 | Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections |
| Q39790167 | Regulation of Marburg virus (MARV) budding by Nedd4.1: a different WW domain of Nedd4.1 is critical for binding to MARV and Ebola virus VP40. |
| Q40303984 | Replication of Marburg virus in human endothelial cells. A possible mechanism for the development of viral hemorrhagic disease |
| Q34301750 | Rescue of recombinant Marburg virus from cDNA is dependent on nucleocapsid protein VP30 |
| Q40721173 | Research with the Marburg, Lassa and Ebola viruses |
| Q45765640 | Respiratory Marburg virus infection in guinea pigs |
| Q35654347 | Risk Factors Associated with Ebola and Marburg Viruses Seroprevalence in Blood Donors in the Republic of Congo |
| Q28389947 | Risk factors for transmission of Ebola or Marburg virus disease: a systematic review and meta-analysis |
| Q45324637 | Role of Non-local Interactions between CDR Loops in Binding Affinity of MR78 Antibody to Marburg Virus Glycoprotein. |
| Q40176620 | Role of the transmembrane domain of marburg virus surface protein GP in assembly of the viral envelope |
| Q35055198 | Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial |
| Q38860437 | Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial |
| Q34435035 | Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against ebola virus and marburg virus: results of two single-ascending-dose studies |
| Q34440625 | Seasonal pulses of Marburg virus circulation in juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human infection |
| Q40713530 | Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus |
| Q33981578 | Sequence analysis of the Marburg virus nucleoprotein gene: comparison to Ebola virus and other non-segmented negative-strand RNA viruses |
| Q40120406 | Sequencing ebola and marburg viruses genomes using microarrays |
| Q38914892 | Short communication: a cluster of Marburg virus disease involving an infant |
| Q44106241 | Single Dose Trivalent Vesiculovax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge |
| Q34606818 | Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus |
| Q45347041 | Small molecule, big advance against Marburg virus |
| Q39601847 | Sorting of Marburg virus surface protein and virus release take place at opposite surfaces of infected polarized epithelial cells |
| Q34225191 | Spermatogenic transmission of the "Marburg virus". (Causes of "Marburg simian disease") |
| Q40362181 | Stabilization of peroxidase conjugates used in enzyme immunoassay systems to detect Ebola and Marburg virus antigens |
| Q30491838 | Structural Insight into Nucleoprotein Conformation Change Chaperoned by VP35 peptide in Marburg virus |
| Q36043176 | Structural and Functional Studies on the Marburg Virus GP2 Fusion Loop |
| Q27675266 | Structural basis for Marburg virus VP35-mediated immune evasion mechanisms |
| Q35132751 | Structural basis for Marburg virus neutralization by a cross-reactive human antibody |
| Q33877879 | Studies of reservoir hosts for Marburg virus |
| Q40643470 | Study of the treatment-prophylactic effect of immunomodulators in experimental infections, caused by Marburg, Ebola, and Venezuelan equine encephalitis viruses |
| Q47548961 | Successful treatment of Marburg virus with orally administrated T-705 (Favipiravir) in a mouse model |
| Q44090151 | Symposium on Marburg and Ebola viruses |
| Q24301153 | T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus |
| Q40492392 | Taking down Goliaths: new vaccines may spell the end for Ebola, Marburg and Lassa virus infections |
| Q36080908 | Temporal Characterization of Marburg Virus Angola Infection following Aerosol Challenge in Rhesus Macaques |
| Q40663546 | Termini of all mRNA species of Marburg virus: sequence and secondary structure |
| Q43721007 | The "Marburg-virus"-hepatitis. Studies in man and guinea pigs |
| Q40717716 | The GP-protein of Marburg virus contains the region similar to the 'immunosuppressive domain' of oncogenic retrovirus P15E proteins |
| Q52487082 | The Marburg virus (Rhabdovirus simiae) |
| Q43211466 | The Marburg virus (vervet monkey agent) |
| Q27682227 | The Marburg virus VP24 protein interacts with Keap1 to activate the cytoprotective antioxidant response pathway |
| Q38893270 | The Marburg virus group |
| Q45751706 | The Marburg virus outbreak of 1967 and subsequent episodes. |
| Q43645552 | The Marburg virus surface protein GP is phosphorylated at its ectodomain |
| Q47555346 | The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding |
| Q40717856 | The VP35 and VP40 proteins of filoviruses. Homology between Marburg and Ebola viruses. |
| Q34594813 | The VP40 protein of Marburg virus exhibits impaired budding and increased sensitivity to human tetherin following mouse adaptation |
| Q40688834 | The asialoglycoprotein receptor is a potential liver-specific receptor for Marburg virus |
| Q45790521 | The complete nucleotide sequence of the Popp (1967) strain of Marburg virus: a comparison with the Musoke (1980) strain. |
| Q41822299 | The cytoplasmic domain of Marburg virus GP modulates early steps of viral infection |
| Q53857092 | The detection of the Marburg virus antigen by solid-phase immunoenzyme analysis |
| Q43480509 | The effect of the methods for producing an experimental Marburg virus infection on the characteristics of the course of the disease in green monkeys |
| Q33724407 | The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis |
| Q53851025 | The immunogenic properties of Marburg virus proteins |
| Q37157191 | The marburg virus 3' noncoding region structurally and functionally differs from that of ebola virus |
| Q40589969 | The matrix protein of Marburg virus is transported to the plasma membrane along cellular membranes: exploiting the retrograde late endosomal pathway |
| Q45810085 | The morbid anatomy of Marburg virus disease |
| Q43811893 | The morphology and pathogenesis of "Marburg virus" hepatitis |
| Q40863379 | The nasty viruses--Lassa, Marburg, and Ebola |
| Q42604182 | The nucleoprotein of Marburg virus is phosphorylated |
| Q40970230 | The nucleoprotein of Marburg virus is target for multiple cellular kinases |
| Q42609286 | The nucleotide sequence of the L gene of Marburg virus, a filovirus: homologies with paramyxoviruses and rhabdoviruses |
| Q34435193 | The origin and evolution of Ebola and Marburg viruses |
| Q44181555 | The pathogenesis and epidemiology of the "Marburg-virus" infection |
| Q45795370 | The pathology of Marburg virus disease |
| Q41831301 | The sensitivity of different cell culture lines to the Marburg virus |
| Q46565032 | The sensitivity of different experimental animals to the Marburg virus |
| Q45732205 | The study of transcription and replication of the Marburg virus using a minireplicon system constructed on the basis of viral genome [corrected]. |
| Q40062330 | Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. |
| Q33785253 | Three of the four nucleocapsid proteins of Marburg virus, NP, VP35, and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes |
| Q38258245 | Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses |
| Q40564597 | Titration of Ebola and Marburg viruses by plaque formation under semi liquid agar |
| Q36080864 | Transcriptional Profiling of the Immune Response to Marburg Virus Infection |
| Q39700080 | Tsg101 is recruited by a late domain of the nucleocapsid protein to support budding of Marburg virus-like particles |
| Q24670567 | Tyro3 family-mediated cell entry of Ebola and Marburg viruses |
| Q39590625 | Ultrastructural organization of recombinant Marburg virus nucleoprotein: comparison with Marburg virus inclusions |
| Q21090501 | Unexpected inheritance: multiple integrations of ancient bornavirus and ebolavirus/marburgvirus sequences in vertebrate genomes |
| Q42371906 | Unveiling a Drift Resistant Cryptotope within Marburgvirus Nucleoprotein Recognized by Llama Single-Domain Antibodies |
| Q33650203 | Uveal involvement in Marburg virus disease |
| Q40361641 | VP24 of Marburg virus influences formation of infectious particles |
| Q39682541 | VP40, the matrix protein of Marburg virus, is associated with membranes of the late endosomal compartment |
| Q27485491 | Vaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus Infections |
| Q44090924 | Vaccines against Ebola and Marburg viruses show promise in primate studies |
| Q24652215 | Vacuolar protein sorting pathway contributes to the release of Marburg virus |
| Q38887552 | Variation in the glycoprotein and VP35 genes of Marburg virus strains |
| Q34120895 | Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates |
| Q34598925 | Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses |
| Q34542167 | Viral haemorrhagic fevers caused by Lassa, Ebola and Marburg viruses |
| Q40518184 | Viral hemorrhagic fevers--Ebola hemorrhagic fever, Marburg virus disease, and Lassa fever |
| Q46324937 | Viral load among patients infected with Marburgvirus in Angola |
| Q21134043 | Virological and serological findings in Rousettus aegyptiacus experimentally inoculated with vero cells-adapted hogan strain of Marburg virus |
| Q33445503 | Virus inactivation in bone tissue transplants (femoral heads) by moist heat with the 'Marburg bone bank system'. |
| Q36845999 | Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges). |
| Q40511451 | Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections |
| Q54053376 | [Animal experiments on the "Marburg-virus"-hepatitis. Studies on guinea pigs]. |
| Q53950609 | [Antibodies against the Marburg virus among human populations in the southeastern Central African Republic] |
| Q44287423 | [Stability of Marburg virus to lyophilization process and subsequent storage at different temperatures]. |
| Q54166353 | [The pathological anatomy of the marburg virus disease] |
| Q45325246 | siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease |
| Q113517788 | Template:Taxonomy/Marburgvirus | template has topic | P1423 |
| Q6418650 | Kitum Cave | significant event | P793 |